Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data

Blood Adv. 2024 Apr 9;8(7):1683-1686. doi: 10.1182/bloodadvances.2023011190.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Humans
  • Red-Cell Aplasia, Pure* / drug therapy
  • Red-Cell Aplasia, Pure* / etiology
  • Transplantation, Homologous

Substances

  • daratumumab
  • Antibodies, Monoclonal